
    
      Eligible subjects will be enrolled and randomized to receive one of the four treatments
      (three dose levels of IMO-8400 or Saline Placebo). Treatments will be administered once
      weekly by subcutaneous injections. Subjects will received treatment for 12 weeks and then be
      followed for an additional 6 weeks to assess the durability of the response.
    
  